{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Combination+3&page=2", "query": { "intervention": "Chemotherapy Combination 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Combination+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T01:46:33.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05241873", "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Neoplasm Malignant", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Neoplasms", "Neoplasms by Site", "Lung Diseases", "Respiratory Tract Disease", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Adenocarcinoma", "Carcinoma", "Neoplasms by Histologic Type", "EGFR Exon 20 Mutation", "EGFR Exon 20 Insertion Mutation", "EGFR Activating Mutation", "Antineoplastic Agents", "Metastatic Lung Cancer", "Brain Metastases", "EGFR-mutated NSCLC", "EGFR Atypical Mutations, Including G719X and L861Q" ], "interventions": [ { "name": "BLU-451", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2022-03-04", "completion_date": "2024-07-31", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05241873" }, { "nct_id": "NCT00001045", "title": "Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Nevirapine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": "1998-10", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 57, "location_summary": "Los Angeles, California • San Francisco, California • San Jose, California + 34 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001045" }, { "nct_id": "NCT02628236", "title": "Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Keratosis, Actinic" ], "interventions": [ { "name": "Aminolevulinic Acid (ALA)", "type": "DRUG" }, { "name": "BLU-U", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "DUSA Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2016-02", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 2, "location_summary": "Austin, Texas • College Station, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628236" }, { "nct_id": "NCT06911502", "title": "A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Golcadomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-07-28", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06911502" }, { "nct_id": "NCT05590377", "title": "A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Modakafusp Alfa", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-23", "completion_date": "2024-05-22", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 13, "location_summary": "Gilbert, Arizona • Los Angeles, California • Fort Wayne, Indiana + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05590377" }, { "nct_id": "NCT02668653", "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 539, "start_date": "2016-09-01", "completion_date": "2023-06-16", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 11, "location_summary": "Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02668653" }, { "nct_id": "NCT02442635", "title": "Yoga During Chemotherapy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Sleep Disturbance", "Fatigue" ], "interventions": [ { "name": "Yoga", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2015-05", "completion_date": "2019-10-01", "has_results": false, "last_update_posted_date": "2019-11-14", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02442635" }, { "nct_id": "NCT03043599", "title": "Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Thoracic Radiation Therapy", "type": "RADIATION" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2017-02-13", "completion_date": "2023-11-16", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043599" }, { "nct_id": "NCT05286814", "title": "PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (Mcrc)", "Intrahepatic Cholangiocarcinoma (Icc)", "Intrahepatic Bile Duct Cancer", "Colorectal Neoplasms", "Colorectal Cancer", "Cholangiocarcinoma", "Bile Duct Neoplasms", "Bile Duct Cancer", "Adrenocortical Carcinoma (ACC)", "Adrenal Cortical Carcinoma", "Adrenal Gland Cancer", "Adrenal Gland Neoplasms", "Adrenal Cortex Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "PDS01ADC", "type": "DRUG" }, { "name": "Intera 3000 Hepatic Artery Infusion Pump (HAIP)", "type": "DEVICE" }, { "name": "Floxuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 70, "start_date": "2022-10-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05286814" }, { "nct_id": "NCT06892548", "title": "A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Lung Cancer" ], "interventions": [ { "name": "BNT324", "type": "BIOLOGICAL" }, { "name": "BNT327", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2025-05-02", "completion_date": "2032-05", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-30T01:46:33.637Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06892548" } ] }